US 12,344,842 B2
Compositions and methods for treating and preventing macular degeneration
Samuel Wadsworth, Shrewsbury, MA (US); Abraham Scaria, Framingham, MA (US); and Chi-Chao Chan, Burlingame, CA (US)
Assigned to Genzyme Corporation, Cambridge, MA (US); and The United States of America, as Represented by the Secretary, Department of Health and Human Services, Bethesda, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US); and The United States of America, as Represented by the Secretary, Department of Health and Human Services, Rockville, MD (US)
Filed on Mar. 31, 2020, as Appl. No. 16/835,913.
Application 16/835,913 is a division of application No. 14/785,159, granted, now 10,640,771, previously published as PCT/US2014/034538, filed on Apr. 17, 2014.
Claims priority of provisional application 61/813,014, filed on Apr. 17, 2013.
Prior Publication US 2021/0040484 A1, Feb. 11, 2021
Int. Cl. C12N 15/113 (2010.01); A61K 38/17 (2006.01); C07K 14/715 (2006.01)
CPC C12N 15/1136 (2013.01) [A61K 38/1793 (2013.01); C07K 14/7155 (2013.01); C07K 2319/30 (2013.01); C12N 2750/14143 (2013.01)] 16 Claims
 
1. A method of reducing lipofuscin or glycogen deposits in a diseased eye of a mammalian subject comprising intravitreally administering to the diseased eye of the subject a composition comprising a recombinant vector encoding a fusion protein comprising an IL 17 inhibitor and a multimerization domain, wherein the IL17 inhibitor is a soluble IL17A receptor capable of binding and modulating the activity of IL17A, wherein the recombinant vector is a recombinant adeno-associated virus serotype 2 (rAAV2) virion.